Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 29c; offers guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.95, $0.29 worse than the analyst estimate of $4.24. Revenue for the quarter came in at $892.8 million versus the consensus estimate of $896.9 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2023 EPS of $16.90-$17.85, versus the consensus of $17.44. Jazz Pharmaceuticals sees FY2023 revenue of $3.675-3.875 billion, versus the consensus of $3.78 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
• UBS cuts KOSPI target by nearly 10% to reflect higher rates